Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy
Open Access
- 1 July 2016
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 24 (7) , 1302-1311
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Collagen VII plays a dual role in wound healingJournal of Clinical Investigation, 2013
- Rat Model for Dominant Dystrophic Epidermolysis Bullosa: Glycine Substitution Reduces Collagen VII Stability and Shows Gene-Dosage EffectPLOS ONE, 2013
- Exon 87 skipping of the COL7A1 gene in dominant dystrophic epidermolysis bullosaThe Journal of Dermatology, 2010
- Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse ModelMolecular Therapy, 2010
- Dominant-negative Effects of COL7A1 Mutations Can be Rescued by Controlled Overexpression of Normal Collagen VIIJournal of Biological Chemistry, 2009
- Injection of Recombinant Human Type VII Collagen Corrects the Disease Phenotype in a Murine Model of Dystrophic Epidermolysis BullosaMolecular Therapy, 2009
- Characterization of Molecular Mechanisms Underlying Mutations in Dystrophic Epidermolysis Bullosa Using Site-directed MutagenesisJournal of Biological Chemistry, 2008
- A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapyJournal of Clinical Investigation, 2008
- Fibroblasts Show More Potential as Target Cells than Keratinocytes in COL7A1 Gene Therapy of Dystrophic Epidermolysis BullosaJournal of Investigative Dermatology, 2006
- Immunohistochemical and mutation analyses demonstrate that procollagen VII is processed to collagen VII through removal of the NC-2 domain.Journal of Cell Biology, 1995